Further studies are needed to evaluate the potential role of afamin, ApoA4, and ApoA2 as predictive biomarkers for IR-related diseases such as T2D, DKD, CVD, and NASH. This evidence concerns the gene APOA2 and metabolic dysfunction-associated steatohepatitis.